Cynapsus Therapeutics Inc Share Price

Stocks

Delayed Toronto S.E.			5-day change	1st Jan Change
- ^CAD	-.--%		+0.21%	-

03/06	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
03/06	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT

03/06	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
03/06	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT
03/06	CoTec JV, HyProMag USA, to Commence Preparatory Work for Project Execution Phase at Dallas-Fort Worth Texas Hub	MT
20/05	CoTec Releases Updated Mineral Resource and "Positive" PEA for Lac Jeannine Iron Tailings Project; Lost Near 10% on Tuesday	MT
11/24/11	Mkango and CoTec Brief: Mkango Subsidiary, Maginito, And CoTec Appointed Lead Engineers BBA And Pegasus To Complete Feasibility Study for HyProMag USA	MT
29/24/29	CoTec Holdings Outlines Key Targets For 2024	MT
03/24/03	Mkango Surges Near 12% As Forms HyProMag Joint Venture In US With CoTec	MT
10/23/10	Mkango Surges 11% As Says To Commence Feasibility Study For Proposed US Operation With CoTec	MT
10/23/10	Mkango, CoTec To Commence Feasibility Study For Proposed US Operation	MT
02/23/02	CoTec Completed Conversion of 2 Million Pounds Mkango Loan Note to Double Equity Position in Maginito to 20.6%	MT
14/23/14	Mkango Down Near 3% As Agrees To Form US Joint Venture With CoTec Holdings	MT
14/23/14	CoTec Holdings, Mkango To Form US Joint Venture	MT
30/23/30	Kings Chapel Increases Stake In CoTec Holdings	MT

06/05	COPPER INTELLIGENCE TO FORM AN EARLY-STAGE EXPLORATION JOINT VENTURE WITH COTEC TO TARGET PROCESSING HISTORICAL COPPER TAILINGS OPPORTUNITIES IN THE DEMOCRATIC REPUBLIC OF CONGO	PR
01/16/01	Cynapsus Therapeutics : Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics	PU
29/16/29	Cynapsus Therapeutics : Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL
15/16/15	Cynapsus Therapeutics : Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson's Disease Clinical Study Allowing for At-Home Titration	GL
12/16/12	Cynapsus Therapeutics : Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CYNAPSUS THERAPEUTICS INC	-.--%	+0.21%	-	-	0
WUXI APPTEC CO., LTD.	+2.41%	-6.33%	+43.43%	+71.02%	6.33TCr
ARGENX SE	-0.15%	+7.50%	+11.01%	+73.48%	5.49TCr
LONZA GROUP AG	+0.57%	+4.60%	+10.07%	+92.86%	5.33TCr
IQVIA HOLDINGS INC.	+0.24%	+4.38%	+26.69%	+51.65%	4.58TCr
BEONE MEDICINES AG	-1.14%	+2.46%	+21.97%	+124.11%	4.35TCr
REVOLUTION MEDICINES, INC.	-0.33%	+5.85%	+252.49%	+926.26%	4.02TCr
CELLTRION, INC.	+0.05%	+6.75%	+14.48%	+56.75%	3.35TCr
WUXI BIOLOGICS (CAYMAN) INC.	+1.19%	-5.84%	+27.86%	-0.65%	2.37TCr
GENMAB A/S	-0.38%	+5.68%	+36.43%	+27.54%	2.38TCr
Average	+0.26%	+0.33%	+49.38%	+158.11%	4.24TCr
Weighted average by Cap.	+0.40%	+0.55%	+47.75%	+159.83%